Inlet Private Wealth LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 13,536 shares of the company’s stock, valued at approximately $1,747,000. Johnson & Johnson accounts for 0.9% of Inlet Private Wealth LLC’s portfolio, making the stock its 27th biggest position.
Several other hedge funds and other institutional investors also recently modified their holdings of JNJ. Vanguard Group Inc lifted its holdings in shares of Johnson & Johnson by 1.5% during the third quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after acquiring an additional 3,235,861 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.5% during the third quarter. Vanguard Group Inc. now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after acquiring an additional 3,235,861 shares during the period. Morgan Stanley lifted its holdings in shares of Johnson & Johnson by 6.3% during the third quarter. Morgan Stanley now owns 22,920,470 shares of the company’s stock valued at $3,166,921,000 after acquiring an additional 1,352,484 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Johnson & Johnson by 2,178.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 649,040 shares of the company’s stock valued at $83,759,000 after acquiring an additional 620,558 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. lifted its holdings in shares of Johnson & Johnson by 58.2% during the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 1,602,167 shares of the company’s stock valued at $221,371,000 after acquiring an additional 589,288 shares during the period. 67.20% of the stock is owned by institutional investors.
Johnson & Johnson stock opened at $139.05 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99. The stock has a market capitalization of $373.06 billion, a P/E ratio of 17.00, a price-to-earnings-growth ratio of 2.40 and a beta of 0.67.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 11th. Investors of record on Tuesday, May 28th will be issued a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.73%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.90. The ex-dividend date of this dividend is Friday, May 24th. Johnson & Johnson’s payout ratio is currently 44.01%.
JNJ has been the subject of a number of analyst reports. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, January 16th. Morgan Stanley lifted their price objective on Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a report on Wednesday, April 17th. Wells Fargo & Co reissued an “outperform” rating and set a $152.00 price objective (down from $162.00) on shares of Johnson & Johnson in a report on Monday, January 14th. Citigroup lifted their price objective on Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a report on Monday, February 25th. Finally, Barclays reaffirmed an “equal weight” rating and issued a $135.00 price target (down from $137.00) on shares of Johnson & Johnson in a report on Wednesday, January 23rd. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $146.90.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/05/12/13536-shares-in-johnson-johnson-jnj-purchased-by-inlet-private-wealth-llc.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: What are different types of coverage ratios?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.